Fundamental, Research

Implications of the Medicare Price Negotiations Announcement for BMY and JNJ

Sel Hardy, VP of Equity Research
05 September 2023

Summary

The Centers for Medicare & Medicaid Services (CMS) released a list of 10 top-selling prescription drugs to be negotiated with Medicare. The market reaction has been limited as the list was expected. Companies' revenue risk is manageable as the drugs selected are no longer a large portion of their portfolios. Some drugs will lose their exclusivity around or after 2026, when the negotiated prices go into effect. Bristol Myers Squibb and Johnson & Johnson are at highest risk of revenue loss by 2026.


Want to learn more? Download the Report.

Solutions

Fundamental Equity Research
Gain a comprehensive view of global themes, industries, and companies.

Related Insights

FDA Action on Aspartame Unlikely

FDA Action on Aspartame Unlikely

Recent reports that the World Health Organization (WHO) will reclassify aspartame...
Read more
Johnson & Johnson (JNJ): Texas Two-Step Takes a Spill

Johnson & Johnson (JNJ): Texas Two-Step Takes a Spill

Johnson & Johnson (JNJ: Talc Bankruptcy Opinion and Implications
Read more
May 2023 PDUFA Calendar

May 2023 PDUFA Calendar

Delays in approvals due to disrupted work schedules at FDA because of the coronavirus...
Read more